Jonathan D. Kay

Jonathan D. Kay

Rheumatology

119 Belmont Street
Worcester, MA 01605

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 134 publications

Longitudinal peripheral blood multi-omic profiling in seropositive individuals identifies immune endotypes and predictive models for future rheumatoid arthritis conversion.

Longitudinal peripheral blood multi-omic profiling in seropositive individuals identifies immune endotypes and predictive models for future rheumatoid arthritis conversion.

Journal: medRxiv : the preprint server for health sciences

Published: February 27, 2026

Greater HIV Viral Load Suppression in Patients Using an Integrated Health System Specialty Pharmacy.

Greater HIV Viral Load Suppression in Patients Using an Integrated Health System Specialty Pharmacy.

Journal: Journal of pharmacy practice

Published: September 04, 2025

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

Journal: RMD open

Published: June 11, 2025

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis.

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: June 05, 2025

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: June 05, 2025

Disparities in Diagnosis: A Call for Equity in Radiographic Axial Spondyloarthritis Care.

Disparities in Diagnosis: A Call for Equity in Radiographic Axial Spondyloarthritis Care.

Journal: The Journal of rheumatology

Published: February 15, 2025

Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges.

Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges.

Journal: Seminars in arthritis and rheumatism

Published: January 06, 2025

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.

Journal: Annals of the rheumatic diseases

Published: October 11, 2024

Axial spondyloarthritis guidelines - aiming for maximum impact.

Axial spondyloarthritis guidelines - aiming for maximum impact.

Journal: Current opinion in rheumatology

Published: April 25, 2024

Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.

Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.

Journal: Trials

Published: March 18, 2024

American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022.

American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 26, 2024

Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.

Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.

Journal: RMD open

Published: January 02, 2024

Showing 1-12 of 134

Last Updated: 09/26/2026